{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:36:41Z","timestamp":1783528601223,"version":"3.55.0"},"reference-count":9,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase inhibitors represent important tools in the therapeutic armamentarium against chronic lymphocytic leukemia (CLL) and other B-lymphoproliferative disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>We describe herein a unique 65-year-old patient who presented with bilateral foot pain four months after starting treatment with ibrutinib for CLL. Of note, the patient had previously been diagnosed with gout, and was taking allopurinol prophylactically at the time of the event. Compliance with allopurinol was in excess of 99%. Yet, he was diagnosed with acute gout flare of bilateral first metatarsophalangeal (MTP) joints. Management &amp; Outcome: Ibrutinib dose was reduced by one third, and the patient\u2019s gout flare up was treated with ibuprofen as needed. After symptoms abated, ibrutinib was continued at 2\/3rds of the dose, with an excellent CLL control. The patient tolerated this dose without any further adverse effects. Discussion\/Conclusions: We have reported a unique side effect of acute bilateral first MTP joint gout flare likely triggered by ibrutinib use for CLL while the patient was taking a xanthine oxidase inhibitor. The mechanism by which ibrutinib caused this phenomenon remains to be elucidated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211029703","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T02:29:11Z","timestamp":1625538551000},"page":"442-444","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-5355","authenticated-orcid":false,"given":"Jaspreet","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Medicine, Eisenhower Health, Eisenhower Health, Rancho Mirage, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-6153","authenticated-orcid":false,"given":"Shahaf","family":"Tuler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Eisenhower Health, Eisenhower Health, Rancho Mirage, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-8394","authenticated-orcid":false,"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[{"name":"Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA"},{"name":"UC San Diego Health, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"bibr1-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2014.50.4.2133570"},{"key":"bibr2-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"bibr3-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr4-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00512-0"},{"key":"bibr5-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"key":"bibr6-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.02.001"},{"key":"bibr7-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218772327"},{"key":"bibr8-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217718617"},{"key":"bibr9-10781552211029703","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-591875"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211029703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211029703","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211029703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:12Z","timestamp":1777688712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211029703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/10781552211029703"],"URL":"https:\/\/doi.org\/10.1177\/10781552211029703","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}